MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412656 | Name: Zoledronate trisodium hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zoledronate trisodium is a Bone Resorption Inhibitor and Osteoporosis Therapy Adjunct

Chemical Structure

Zoledronate trisodium hydrate
Zoledronate trisodium hydrate
CAS#165800-08-8 (trisodium hydrate)

Theoretical Analysis

MedKoo Cat#: 412656

Name: Zoledronate trisodium hydrate

CAS#: 165800-08-8 (trisodium hydrate)

Chemical Formula: C25H39N10Na15O37P10

Exact Mass:

Molecular Weight: 1726.20

Elemental Analysis: C, 17.40; H, 2.28; N, 8.11; Na, 19.98; O, 34.29; P, 17.94

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
118072-93-8 (free acid) 165800-06-6 (free acid hydrate) 131654-46-1 (disodium) 827573-11-5 (trisodium) 165800-07-7 (disodium hydrate) 165800-08-8 (trisodium hydrate)
Synonym
Zoledronate trisodium, Zoledronate trisodium hydrate
IUPAC/Chemical Name
Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium compound with water (5:2)
InChi Key
HYMYRPXSMHJPGD-UHFFFAOYSA-A
InChi Code
InChI=1S/5C5H10N2O7P2.15Na.2H2O/c5*8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;;;;;;;;;;;;;;;;/h5*1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;;;;;;;;;;;;;;;2*1H2/q;;;;;15*+1;;/p-15
SMILES Code
OC(P([O-])([O-])=O)(P([O-])(O)=O)CN1C=CN=C1.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN2C=CN=C2.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN3C=CN=C3.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN4C=CN=C4.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN5C=CN=C5.[H]O[H].[H]O[H].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,726.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082. Epub 2018 Oct 1. PMID: 30575489. 2: Bergua A, Hohberger B. Zoledronsäure-induzierte Panuveitis [Zoledronate- induced panuveitis]. Ophthalmologe. 2018 Jul;115(7):592-594. German. doi: 10.1007/s00347-017-0538-3. PMID: 28748264. 3: Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res. 2019 Dec;34(12):2220-2228. doi: 10.1002/jbmr.3853. Epub 2019 Oct 14. PMID: 31433518. 4: Leong I. Zoledronate prevents fractures in osteopenia. Nat Rev Endocrinol. 2018 Dec;14(12):688. doi: 10.1038/s41574-018-0116-z. PMID: 30353074. 5: Dong W, Qi M, Wang Y, Feng X, Liu H. Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1195-1202. doi: 10.1016/j.bbrc.2018.10.059. Epub 2018 Oct 13. PMID: 30322621. 6: Zhao Z, Shen W, Zhu H, Lin L, Jiang G, Zhu Y, Song H, Wu L. Zoledronate inhibits fibroblasts' proliferation and activation via targeting TGF-β signaling pathway. Drug Des Devel Ther. 2018 Sep 17;12:3021-3031. doi: 10.2147/DDDT.S168897. PMID: 30271117; PMCID: PMC6147205. 7: He Y, Bao W, Wu XD, Huang W, Chen H, Li Z. Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta- Analysis. Biomed Res Int. 2019 Sep 22;2019:9541485. doi: 10.1155/2019/9541485. PMID: 31663000; PMCID: PMC6778941. 8: Zhao QH, Zhang XS, Wu K, Zhang J, Xia TF, Chen J, Qin ZS, Pang LQ. Preparation of Zoledronate liposome and its impact on apoptosis of Kupffer cells in rat liver. Acta Cir Bras. 2018 Dec;33(12):1052-1060. doi: 10.1590/s0102-865020180120000002. PMID: 30624510. 9: Schenk A, Lux C, Lane J, Martin O. Evaluation of Zoledronate as Treatment for Hypercalcemia in Four Dogs. J Am Anim Hosp Assoc. 2018 Nov/Dec;54(6):e54604. doi: 10.5326/JAAHA-MS-6681. Epub 2018 Oct 1. PMID: 30272485. 10: Zandi M, Shokri A, Mousavi M, Rajaei S, Mohammad Gholi Mezerji N. Does zoledronate therapy make mandibular bone susceptible to fracture? A radiographical and biomechanical study in rats. Injury. 2018 Oct;49(10):1746-1749. doi: 10.1016/j.injury.2018.07.006. Epub 2018 Jul 6. PMID: 30007517.

View History

L-163,101

L-163,101

Zotiraciclib HCl

Zotiraciclib HCl

ICI-58301

ICI-58301

Azido-PEG11-t-butyl ester

Azido-PEG11-t-butyl ester

S17834

S17834

VU6031545

VU6031545